Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Some analysts raised their eyebrows at Oramed's ($ORMP) preliminary midstage oral insulin data in late January. Now the Jerusalem-based company has announced further details of the trial that bring to light a dosing issue, and shares have continued their downward spiral ever since.
Beyond the data showing the pill is safe and well-tolerated, which Oramed announced in January, the new results include details regarding the study design, further safety data and pharmacodynamics of the glucose control of the company's ORMD-0801 oral insulin capsule for Type 2 diabetes.
http://www.fiercedrugdelivery.com/s...ompromised-study-and-shares-contin/2014-04-30
Beyond the data showing the pill is safe and well-tolerated, which Oramed announced in January, the new results include details regarding the study design, further safety data and pharmacodynamics of the glucose control of the company's ORMD-0801 oral insulin capsule for Type 2 diabetes.
http://www.fiercedrugdelivery.com/s...ompromised-study-and-shares-contin/2014-04-30
